What is Illumina (ILMN)?
Illumina is a biotechnology company specializing in the development and manufacturing of integrated systems for the analysis of genetic variation and function. The company provides sequencing and array-based solutions for genetic research, enabling advancements in areas such as genomics, molecular biology, and personalized medicine. Illumina's technologies are widely used in academic, government, pharmaceutical, and biotechnology institutions to facilitate genetic analysis and contribute to scientific discovery. The company's product portfolio includes instruments, consumables, and software that support a range of applications including whole-genome sequencing, targeted resequencing, gene expression profiling, and genotyping. Illumina plays a significant role in the genomics industry by advancing the understanding of genetic information and its implications for health and disease. Its innovations have contributed to the growth of precision medicine and have supported research in oncology, reproductive health, and genetic disease. Headquartered in San Diego, California, Illumina operates globally, serving customers in research and clinical markets.
Illumina Stock Price Today: Live Overview
The price today is shaped by ongoing trading, with Illumina currently priced at $127.16. The intraday range extends from $119.9 to $127.29, showing a daily move of +2.9716%.
FAQ: Illumina (ILMN)
What is the current price of ILMN stock?
Illumina's stock price is currently $127.16.
Does ILMN pay dividends?
Illumina pays dividends via cash distributions (if applicable).
Does ILMN have a formal corporate presence or regional headquarters in the UAE?
Illumina operates in the UAE via partners and distributors without a direct office.
What is ILMN best known for?
Illumina is most famous for its genomic sequencing technologies.
What assets are typically shown together with ILMN?
Commonly shown alongside ILMN: iShares MSCI India Small-Cap ETF, iShares MSCI India Small-Cap ETF, Fulgent Genetics, Inc.
Latest shares articles



